Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Huawei legal chief Song Liuping told CNBC that the company is in the "early phase" of talks with Verizon over paying royalties.Technologyread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
U.S. President Donald Trump on Thursday asked India to withdraw retaliatory tariffs that New Delhi imposed this month, calling the duties "unacceptable."World Economyread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
New medicines are increasingly targeting the genetic drivers of disease. But what if medicine could go a step further and actually correct the genetic defect itself?
That's what researchers aim to do with Crisp, a new technology that enables gene editing in a simpler way than ever before.
"It allows precision changes to be made to DNA at the level of a single letter in the DNA code of a human cell, for example," explained Jennifer Doudna, a professor at the University of California, Berkeley, and a pioneer of the technology. "And it's simple enough to use that scientists all over the world have been able to get access to this technology and start testing it."
The name Crispr (CRISPR) stands for Clustered Regularly Interspaced Short Palindromic Repeats. It sounds complicated, but, as Doudna points out, it's actually the technology's simplicity that's got the scientific community so excited.
Think of it like a search-and-rescue mission for DNA. Crispr uses guide RNA as a homing device; it's designed in a lab to match up with a section of DNA designated for editing. In therapeutic uses, this could be a genetic abnormality that causes disease.
That guide molecule is joined with an enzyme known as Cas9 (CRISPR's fuller name is actually CRISPR-Cas9). The enzyme acts like scissors, making a cut in the DNA where the RNA guided. By adding DNA with the correct sequence, scientists hope to be able to correct the underlying genetic defects that cause disease.
"There's already a lot of active research going on using the Crispr technology to fix diseases like Duchenne muscular dystrophy or cystic fibrosis or Huntington's disease," Doudna said. "They're all diseases that have known genetic causes, and we now have the technology that can repair those mutations to provide, we hope, patients with a normal life."
Several companies have been formed to leverage the technology, including Editas Medicine, Intellia Therapeutics, Caribou Biosciences and the aptly named Crispr Therapeutics. Doudna is affiliated with both Intellia and Caribou.
Editas had an initial public offering in February, and the stock has nearly doubled since. Intellia went public in early May, and its stock has since gained 31 percent. Both companies have market values of more than $1 billion. Neither is yet in human testing.